Susquehanna Fundamental Investments LLC Buys Shares of 198,947 Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 198,947 shares of the company's stock, valued at approximately $436,000. Susquehanna Fundamental Investments LLC owned about 0.28% of Ventyx Biosciences at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. MetLife Investment Management LLC boosted its position in Ventyx Biosciences by 76.0% during the fourth quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after acquiring an additional 11,543 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Ventyx Biosciences during the fourth quarter worth $347,000. Walleye Capital LLC grew its position in shares of Ventyx Biosciences by 22.5% in the fourth quarter. Walleye Capital LLC now owns 477,788 shares of the company's stock valued at $1,046,000 after purchasing an additional 87,686 shares during the period. Barclays PLC increased its stake in Ventyx Biosciences by 14.2% in the fourth quarter. Barclays PLC now owns 91,669 shares of the company's stock valued at $200,000 after purchasing an additional 11,374 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Ventyx Biosciences by 99.1% during the fourth quarter. Renaissance Technologies LLC now owns 624,500 shares of the company's stock worth $1,368,000 after buying an additional 310,800 shares during the period. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "neutral" rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th.

Ventyx Biosciences Stock Up 5.1 %

VTYX stock opened at $1.45 on Friday. The company has a market cap of $103.18 million, a price-to-earnings ratio of -0.61 and a beta of 0.75. The business has a fifty day simple moving average of $1.24 and a 200-day simple moving average of $1.83. Ventyx Biosciences, Inc. has a 52 week low of $0.78 and a 52 week high of $5.66.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.13. As a group, analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.